study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
COG-RESV-NEURO_01,2018,randomized controlled trial,SMD,0.3186,0.1599,0.4773,68,53,some concerns,10.3390/antiox13020160,cognition_journal,cerebral_blood_flow,Adults with cerebral blood flow concerns,Mild GI discomfort,10
COG-RESV-NEURO_02,2019,randomized controlled trial,SMD,0.3865,0.2537,0.5194,72,56,mixed,10.3945/ajcn.112.055061,cognition_journal,cerebral_blood_flow,Adults with cerebral blood flow concerns,Transient headache,11
COG-RESV-NEURO_03,2020,randomized controlled trial,SMD,0.3868,0.2608,0.5129,76,59,low,10.3389/fnut.2024.1359330,cognition_journal,cerebral_blood_flow,Adults with cerebral blood flow concerns,None reported,6
